1. Basal cell carcinoma—a clinical indicator of immunosuppression
- Author
-
Lucian G. Scurtu, Marian Petrica, Francesca Scurtu, Anca Angela Simionescu, Marco I. Popescu, and Olga Simionescu
- Subjects
basal cell carcinoma ,immunosuppression ,skin cancer ,diabetes mellitus ,cancer ,carcinoma ,Medicine (General) ,R5-920 - Abstract
BackgroundBasal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are skin-derived carcinomas. The literature strongly connects SCC with acquired immunosuppression. Current data regarding BCC’s association with immunosuppressive comorbidities are vague. The primary objective of this study was to establish the correlations between BCC and immunosuppressive comorbidities of patients. Materials and methods: We conducted a retrospective cohort study on 275 patients with a histopathological proven diagnosis of BCC from October 2019 to October 2023. Demographic data, BCC characteristics, and patients’ comorbidities were analyzed. Comorbidities were classified as non-immunosuppressant and immunosuppressant (primary and secondary immunodeficiencies).ResultsWe recorded 292 BCCs from 275 patients (142 females, 133 males), with equally distributed skin phototypes. 66.44% of the BCCs were detected in patients with various comorbidities (p
- Published
- 2024
- Full Text
- View/download PDF